Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts
Journal of Clinical and Preventive Cardiology · 2016
DOI: 10.4103/2250-3528.192689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Preventive Cardiology, 2016. Verfasst von ShamannaS Iyengar. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Low density lipoprotein cholesterol (LDL-C) is the target of lipid lowering therapy in subjects who have atherosclerotic cardiovascular disease (ASCVD) or who are at risk of developing it. There have been many debatable issues in this field. Should lifelong statins be prescribed for subjects at low risk of ASCVD in primary prevention? How low one can go in LDL-C lowering and is it safe? Should we treat to target or just administer high or moderate or low intensity statins based on the risk category? What is the role of nonstatin drugs in lipid lowering therapy? Are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9 inhibitors) going to be the game changers? There is an abundance of literature looking at these matters. Statins continue to be the first choice in dyslipidemia management. PCSK9 inhibitors would be a welcome addition to the armamentarium or an attractive alternative in certain situations.
Zitieren
APA
Iyengar, S. (2016). Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts. Journal of Clinical and Preventive Cardiology. https://doi.org/10.4103/2250-3528.192689
Vancouver
Iyengar S. Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts. Journal of Clinical and Preventive Cardiology. 2016. doi:10.4103/2250-3528.192689
BibTeX
@article{Iyengar2016,
author = {Iyengar, ShamannaS},
title = {Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts},
journal = {Journal of Clinical and Preventive Cardiology},
year = {2016},
doi = {10.4103/2250-3528.192689}
}
EUVIMED